Allurion boasts over 17% weight loss with swallowable balloon device
A study noted an average weight loss of 17.6% with Allurion’s device in patients who had no or less than 5% weight loss with GLP-1 drugs.
05 November 2024
05 November 2024
A study noted an average weight loss of 17.6% with Allurion’s device in patients who had no or less than 5% weight loss with GLP-1 drugs.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.